REVVITY INC高管在电话会议中透露,公司第一季度免疫诊断业务出现低个位数百分比的内生性下滑。该数据反映了剔除并购、汇率等外部因素后的核心业务表现。
REVVITY INC高管在电话会议中透露,公司第一季度免疫诊断业务出现低个位数百分比的内生性下滑。该数据反映了剔除并购、汇率等外部因素后的核心业务表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.